C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

About this update from C4 Therapeutics, Inc.

WATERTOWN, Mass. , April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the Stifel 2024 Targeted Oncology Forum taking place virtually from April 16 – April 17, 2024 . Fireside Chat Details: Event: Stifel 2024 Targeted Oncology Forum Date/Time: Tuesday, April 16, 2024 from 10:30 am ET – 10:55 am ET A live webcast will be available on the Investors section of the company’s website at www.c4therapeutics.com . An archived replay of the webcast will be available for approximately 30 days following the live event. About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com . Contacts: Investors: Courtney Solberg Senior Manager, Investor Relations [email protected] Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy [email protected] Source: C4 Therapeutics, Inc.

View stock analysis, news, and events for C4 Therapeutics, Inc.